About the Program:
Target Audience:
This activity is intended for physicians, physician assistants, advanced practice nurses, general practitioners and other health care professionals involved in the treatment and management of patients who have or are at risk of HIV infection.
Learning Objectives:
Upon completion of the program, participants should be able to:
- Recognize and address health care disparities that impact the effective treatment of underserved individuals with HIV, including African Americans, and engage and retain them in HIV care
- Provide effective ARV treatment options to underserved individuals with HIV, including African Americans, and use effective strategies to improve treatment and reduce the risk of new infections with HIV in these populations
- Describe and address risk factors that contribute to the continued spread of HIV, especially in high-risk and underserved populations, including African Americans
- Recognize the unique needs of underserved women with HIV, including African American women, and provide appropriate treatment that addresses these needs
Release Date: April 15, 2022
Expiration Date: April 15, 2023
Estimated time to complete each Module: 30 - 45 minutes
Media: Internet
Computer System Requirements: Internet Connection and Browser
Faculty:
Joseph Eron, MD
Professor of Medicine, School of Medicine
Chief, Division of Infectious Diseases
The University of North Carolina at Chapel Hill
Chapel Hill, North Carolina
Helena Kwakwa, MD, MPH
Director HIV Clinical Services
Philadelphia Department of Public Health
Ambulatory Health Services
Philadelphia, Pennsylvania
Richard A. Elion, MD
Associate Professor of Clinical Medicine
George Washington University Medical Center
Washington, DC
Michelle Cespedes, MD
Associate Professor of Medicine
Division of Infectious Diseases
The Mount Sinai Hospital
New York, New York
Back to Top
Joint Accreditation Statement:
|
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and ViralEd, Inc. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
|
Back to Top
Credit Designation:
Module 1 (Health Care Disparities in HIV):
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Module 2 (Identifying Patients at Risk):
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Module 3 (Reducing Risk in Populations at Risk):
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Module 4 (Diverse Populations at Risk - Evidence-Based Prevention):
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Module 5 (HIV Prevention - What’s on the Horizon):
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
e-Newsletter:
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Back to Top
Disclosure of Conflicts of Interest:
Postgraduate Institute for Medicine (PIM) requires faculty, planners and others in control of educational content to disclose all thier financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineleigible company.
Joseph Eron, MD:
- Consultant/Advisory Board: ViiV, Gilead, GSK, Merck, Janssen (relationship ended)
- Grant/Research Support: Gilead, ViiV, Janssen (relationship ended)
|
Helena Kwakwa, MD:
- Grant/Research Support: ViiV
|
Richard Elion, MD:
- Consultant/Advisory Board: Merck, Gilead, ViiV
- Speakers Bureau/Honoraria for Non-CME: Gilead, ViiV
- Other financial or material suport (Expert Witness): Gilead
|
Michelle Cespedes, MD:
- Consultant/Advisory Board: Gilead, ViiV
|
The PIM planners and others have nothing to disclose.
Back to Top
Method of Participation and Request for Credit
1) Go to http://www.cmeuniversity.com/
2) Login or Create a New Account (will take less than 1 minute)
a) If you receive a message when creating a new account that "the
email you entered is already in use", please click the Forgot my
Username or Password link to have your Username and Password sent to you
via email
b) After logging in, you may be asked to verify/update your information; after doing so, click Save at the bottom of the page
3) Type in 16974 at the top of the page, "Find Post-Test/Evaluation by Course", and click enter
4) Click on the activity title when it appears
5) Choose the type of credit you desire
6) Complete the online Evaluation
7) Receive an immediate CE Certificate to download and/or print for your files
Back to Top
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or
investigational uses of agents that are not indicated by the FDA. The
planners of this activity do not recommend the use of any agent outside
of the labeled indications.
The opinions expressed in the educational activity are those of the
faculty and do not necessarily represent the views of the planners.
Please refer to the official prescribing information for each product
for discussion of approved indications, contraindications, and warnings.
Back to Top
Disclaimer
Participants have an implied responsibility to use the newly acquired
information to enhance patient outcomes and their own professional
development. The information presented in this activity is not meant to
serve as a guideline for patient management. Any procedures,
medications, or other courses of diagnosis or treatment discussed or
suggested in this activity should not be used by clinicians without
evaluation of their patient's conditions and possible contraindications
on dangers in use, review of any applicable manufacturer's product
information, and comparison with recommendations of other authorities.
Back to Top
Computer System Requirements
This program requires HTML 5 enabled web browsers such as: Microsoft Edge, Mozilla Firefox, Apple Safari or Google Chrome.
Back to Top
This activity is supported by an independent educational grant from Gilead Sciences Medical Affairs and Janssen Therapeutics, Division of Janssen Products, LP.
Jointly provided by the Postgraduate Institute for Medicine and ViralEd, Inc.
|